Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at their manufacturing sites. These audits yielded regulatory observations, prompting companies to address the findings. Alkem Laboratories, however, reported no critical issues from a separate Armenian health ministry audit at its Sikkim facility. Source link India News Mekedatu dam project: a… Centre Informs Supreme Court Of… 14 Lakh SIR Forms Identified As… Sebi to simplify process for issue… Stock Market Venture Global Signs 20-Year LNG… Asia-Pacific markets track Wall… Yes Bank allots 10.58 lakh equity… Warren Buffett's Berkshire… Space News NASA Orbiter…